Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, reduces all-cause mortality
and the rate of heart failure hospitalizations in patients with heart failure with reduced …

Aims The long‐term effect of angiotensin receptor–neprilysin inhibitor (ARNI) remains
uncertain in patients who have experienced improvements in left ventricular (LV) systolic …

Angiotensin receptor neprilysin inhibitors (ARNI), a new therapeutic class of agents acting
on the renin angiotensin aldosterone system (RAAS) and neutral endopeptidase system has …

Aims Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril
was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy …

Patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction
have an increased risk of death and heart failure. Numerous clinical studies have …

Background Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor
blockers (ARB) have been shown to have a significant cardioprotective effect in high-risk …

BACKGROUND: Ventricular remodeling after acute myocardial infarction (AMI) is associated
with increased morbidity and mortality. ELITE II study showed that losartan, an angiotensin …

Background Despite the established benefits of angiotensin receptor-neprilysin inhibitor
(ARNI) in heart failure with reduced ejection fraction (HFrEF) across various etiologies, there …

Background: infarction (AMI) can be reduced by the use of sacubitril/valsartan. However, the
therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent. In this paper …

Objective Left ventricular remodelling following a ST-segment elevated myocardial infarction
(STEMI) is an adaptive response to maintain the cardiac output despite myocardial tissue …